Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "magnesium absorption process" refers broadly to how dietary magnesium ions are absorbed from the gastrointestinal tract into the body. This occurs primarily via two mechanisms: Paracellular passive transport—the main route under normal/high luminal concentrations—occurs through tight junctions between enterocytes in the small intestine. The permeability depends on claudin protein expression patterns but remains incompletely understood at the molecular level. Transcellular active transport becomes more important at low luminal concentrations and involves specific ion channels on enterocyte membranes. The most critical known channel is transient receptor potential melastatin member 6 (TRPM6)—a highly selective Mg²⁺ channel expressed mainly in distal small intestine and colon—and its close homolog TRPM7. These channels mediate apical entry of Mg²⁺ into cells; basolateral extrusion mechanisms remain less well defined but may involve sodium gradients. Genetic mutations affecting these channels can result in profound clinical syndromes such as hypomagnesemia with secondary hypocalcemia due to impaired intestinal uptake and excessive urinary loss of magnesium. Certain medications—notably proton pump inhibitors—can also impair this pathway by downregulating channel expression/function. Because this term does not refer specifically to an individual molecule/receptor/protein but rather encompasses several components working together within a physiological context, it should not be considered a canonical drug target per se. If you require structured data for one of its key molecular mediators—for example “Transient receptor potential cation channel subfamily M member 6” (TRPM6)—please specify so that detailed information about that protein can be provided instead.
For PPIs: Inhibit transcellular Mg²⁺ uptake by downregulating/suppressing TRPM6/TRPM7 channel function, leading to reduced intestinal Mg²⁺ entry into epithelial cells. For supplementation: Increase luminal concentration of Mg²⁺ to enhance passive paracellular uptake. No direct pharmacologic agonists/antagonists for the overall "process."
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Magnesium absorption process.